JP2021523733A - 動物病原体由来ポリペプチドおよびその遺伝子工学的利用 - Google Patents

動物病原体由来ポリペプチドおよびその遺伝子工学的利用 Download PDF

Info

Publication number
JP2021523733A
JP2021523733A JP2021506378A JP2021506378A JP2021523733A JP 2021523733 A JP2021523733 A JP 2021523733A JP 2021506378 A JP2021506378 A JP 2021506378A JP 2021506378 A JP2021506378 A JP 2021506378A JP 2021523733 A JP2021523733 A JP 2021523733A
Authority
JP
Japan
Prior art keywords
gene
seq
sequence
amino acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021506378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523733A5 (https=
Inventor
フョードル ウルノフ、
フョードル ウルノフ、
ジョン エー． スタマトヤンノポウロス、
ジョン エー． スタマトヤンノポウロス、
アリステア ピーダヴリュ— ファンネル、
アリステア ピーダヴリュ― ファンネル、
Original Assignee
アルティウス インスティテュート フォー バイオメディカル サイエンスィズ
アルティウス インスティテュート フォー バイオメディカル サイエンスィズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルティウス インスティテュート フォー バイオメディカル サイエンスィズ, アルティウス インスティテュート フォー バイオメディカル サイエンスィズ filed Critical アルティウス インスティテュート フォー バイオメディカル サイエンスィズ
Publication of JP2021523733A publication Critical patent/JP2021523733A/ja
Publication of JP2021523733A5 publication Critical patent/JP2021523733A5/ja
Priority to JP2024198757A priority Critical patent/JP2025037883A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021506378A 2018-04-18 2019-04-18 動物病原体由来ポリペプチドおよびその遺伝子工学的利用 Pending JP2021523733A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024198757A JP2025037883A (ja) 2018-04-18 2024-11-14 動物病原体由来ポリペプチドおよびその遺伝子工学的利用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862659656P 2018-04-18 2018-04-18
US62/659,656 2018-04-18
US201862690905P 2018-06-27 2018-06-27
US62/690,905 2018-06-27
US201862716223P 2018-08-08 2018-08-08
US62/716,223 2018-08-08
US201862738825P 2018-09-28 2018-09-28
US62/738,825 2018-09-28
US201962819237P 2019-03-15 2019-03-15
US62/819,237 2019-03-15
PCT/US2019/028174 WO2019204643A2 (en) 2018-04-18 2019-04-18 Animal pathogen-derived polypeptides and uses thereof for genetic engineering

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024198757A Division JP2025037883A (ja) 2018-04-18 2024-11-14 動物病原体由来ポリペプチドおよびその遺伝子工学的利用

Publications (2)

Publication Number Publication Date
JP2021523733A true JP2021523733A (ja) 2021-09-09
JP2021523733A5 JP2021523733A5 (https=) 2022-04-20

Family

ID=68240638

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506378A Pending JP2021523733A (ja) 2018-04-18 2019-04-18 動物病原体由来ポリペプチドおよびその遺伝子工学的利用
JP2024198757A Pending JP2025037883A (ja) 2018-04-18 2024-11-14 動物病原体由来ポリペプチドおよびその遺伝子工学的利用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024198757A Pending JP2025037883A (ja) 2018-04-18 2024-11-14 動物病原体由来ポリペプチドおよびその遺伝子工学的利用

Country Status (6)

Country Link
US (2) US12312383B2 (https=)
EP (1) EP3781193A4 (https=)
JP (2) JP2021523733A (https=)
AU (1) AU2019256517B2 (https=)
CA (1) CA3097648A1 (https=)
WO (1) WO2019204643A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4010004A4 (en) * 2019-08-07 2023-09-13 Altius Institute For Biomedical Sciences Compositions and methods for modulation of gene expression
JP7507242B2 (ja) * 2020-08-25 2024-06-27 中興通訊股▲ふん▼有限公司 無線ネットワーク一時識別子に関連する方法および装置
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2025034754A2 (en) * 2023-08-08 2025-02-13 Altius Institute For Biomedical Sciences Nucleic acid binding domains and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018601A2 (en) * 2012-07-24 2014-01-30 Cellectis New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
CA2769262C (en) 2009-07-28 2019-04-30 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
EP2660318A1 (en) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US9499592B2 (en) 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
US9410134B2 (en) 2011-06-07 2016-08-09 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt Protein having nuclease activity, fusion proteins and uses thereof
JP6214530B2 (ja) 2011-07-15 2017-10-18 ザ ジェネラル ホスピタル コーポレイション 転写活性化因子様エフェクターの組立て方法
WO2013015220A1 (ja) 2011-07-22 2013-01-31 株式会社東芝 Ｘ線診断装置及び制御プログラム
CA2848417C (en) 2011-09-21 2023-05-02 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
HK1200871A1 (en) 2011-11-16 2015-08-14 Sangamo Therapeutics, Inc. Modified dna-binding proteins and uses thereof
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
DK2825190T3 (en) 2012-03-15 2017-02-27 Cellectis REPEAT VARIABLE DIRESTS FOR TARGETING NUCLEOTIDES
WO2013152220A2 (en) * 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
KR102357105B1 (ko) 2012-09-04 2022-02-08 더 스크립스 리서치 인스티튜트 표적화된 바인딩 특이도를 갖는 키메라 폴리펩타이드들
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
KR102121086B1 (ko) 2012-11-01 2020-06-09 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
CA2891510C (en) 2012-11-16 2022-10-18 Transposagen Biopharmaceuticals, Inc. Site-specific enzymes and methods of use
US9708589B2 (en) 2012-12-18 2017-07-18 Monsanto Technology Llc Compositions and methods for custom site-specific DNA recombinases
EP2951295B1 (en) 2013-02-01 2018-08-01 Cellectis Tevi chimeric endonucleases and their preferential cleavage sites
CA2927965A1 (en) 2013-10-25 2015-04-30 Cellectis Design of rare-cutting endonucleases for efficient and specific targeting dna sequences comprising highly repetitive motives
US9850497B2 (en) 2013-11-04 2017-12-26 Regents Of The University Of Minnesota Gene targeting methods and tools
WO2015164748A1 (en) 2014-04-24 2015-10-29 Sangamo Biosciences, Inc. Engineered transcription activator like effector (tale) proteins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
US20190234874A1 (en) 2016-07-19 2019-08-01 Altius Institute For Biomedical Sciences Methods for fluorescence imaging microscopy
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
KR102455249B1 (ko) 2016-08-24 2022-10-17 상가모 테라퓨틱스, 인코포레이티드 가공된 표적 특이적 뉴클레아제
EP3583203B1 (en) 2017-02-15 2023-11-01 2seventy bio, Inc. Donor repair templates multiplex genome editing
US12264181B2 (en) 2018-06-27 2025-04-01 Altius Institute For Biomedical Sciences Nucleic acid binding domains and methods of use thereof
US12209259B2 (en) 2018-06-27 2025-01-28 Altius Institute For Biomedical Sciences Nucleases for genome editing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018601A2 (en) * 2012-07-24 2014-01-30 Cellectis New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"DE SubName: Full=Avirulence protein AvrBs3 {ECO:0000313|EMBL:KTD30443.1}", DATABASE UNIPROT [ONLINE]，AC A0A0W0WDL4, JPN6023012099, 28 March 2018 (2018-03-28), ISSN: 0005370048 *
"DE SubName: Full=IcmE/DotG protein {ECO:0000313|EMBL:KTD51021.1}", DATABASE UNIPROT [ONLINE]，AC A0A0W0Y1V4, JPN6023012098, 28 March 2018 (2018-03-28), ISSN: 0005370047 *
"DE SubName: Full=Uncharacterized protein {ECO:0000313|EMBL:OGV28801.1}", DATABASE UNIPROT [ONLINE]，AC A0A1G0X562, JPN6023012100, 7 June 2017 (2017-06-07), ISSN: 0005370049 *

Also Published As

Publication number Publication date
US20210115093A1 (en) 2021-04-22
EP3781193A4 (en) 2022-01-26
AU2019256517B2 (en) 2025-05-29
JP2025037883A (ja) 2025-03-18
US20250361275A1 (en) 2025-11-27
US12312383B2 (en) 2025-05-27
AU2019256517A1 (en) 2020-11-12
CA3097648A1 (en) 2019-10-24
WO2019204643A2 (en) 2019-10-24
WO2019204643A3 (en) 2019-11-28
EP3781193A2 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
JP2021523733A (ja) 動物病原体由来ポリペプチドおよびその遺伝子工学的利用
AU2021200127B2 (en) Delivery of negatively charged proteins using cationic lipids
US20250289853A1 (en) Nucleic acid binding domains and methods of use thereof
US10676735B2 (en) High-throughput screening of regulatory element function with epigenome editing technologies
JP6905755B2 (ja) Ｒｎａガイド型エンドヌクレアーゼを使用してゲノム工学における特異性を改善する組成物および方法
ES2808687T3 (es) Métodos y composiciones para escisión dirigida y recombinación
CN111989113B (zh) 用于治疗癌症的包含向导rna和核酸内切酶作活性成分的药物组合物
JP2021164463A (ja) エピゲノム編集のための組成物および方法
EP4434997A2 (en) Delivery of negatively charged proteins using cationic lipids
US12275935B2 (en) Gapped and tunable repeat units for use in genome editing and gene regulation compositions
US11439692B2 (en) Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system
US12209259B2 (en) Nucleases for genome editing
WO2018227755A1 (zh) 用于特异性修复人hbb基因突变的碱基编辑系统、方法、试剂盒及其应用
EP3884063B1 (en) Compositions and methods for detection of cleavage of genomic dna by a nuclease
WO2025034754A2 (en) Nucleic acid binding domains and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240716